drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-NK)
drug_description
Allogeneic (off-the-shelf) bispecific CAR-modified natural killer (NK) cell therapy targeting BCMA and GPRC5D for multiple myeloma; single infusion after lymphodepletion to mediate cytotoxicity against malignant plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Natural Killer Cells
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic bispecific CAR-engineered NK cells recognizing BCMA and GPRC5D on myeloma cells; CAR engagement activates NK cytotoxicity (perforin/granzyme, cytokines) to induce apoptosis of malignant plasma cells and mitigate antigen escape.
drug_name
ACT-001 CAR-NK cell
nct_id_drug_ref
NCT06594211